FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4377029582> ?p ?o ?g. }

• W4377029582 abstract "<b>Abstract ID 24646</b> <b>Poster Board 20</b> Duloxetine (DLX), a dual serotonin and norepinephrine reuptake inhibitor for the treatment of major depressive disorder, is mainly metabolized by CYP1A2 and CYP2D6 in human. Despite DLX has a good tolerance for most patients, the cases with serious liver injury have been reported. Here, we investigated the roles of P450-mediated metabolism in the DLX hepatotoxicity <i>in vitro</i> and <i>in vivo</i>. We found that DLX is less toxic to CYP1A2- or CYP2D6-overexpressed HepG2 cells compared to their counterpart HepG2 cells transduced with empty vector, indicating that P450-mediated metabolism attenuates DLX cytotoxicity to HepG2. The CYP1A2 (α-naphthoflavone and fluvoxamine) or CYP2D6 inhibitors (paroxetine, fluoxetine, and quinidine) significantly enhanced the toxicity of DLX to human primary hepatocytes. In Cyp1a2-knockout (Cyp1a2-KO) and <i>counterpart</i> wild-type (WT) mice, 50 mg/kg or 100 mg/kg (p.o.) of DLX for consecutive 5 days did not significantly increase the plasma ALT and AST levels compared with the vehicle group in both WT and Cyp1a2-KO mice, suggesting that Cyp1a2 is not a fundamental contributor to DLX detoxification at least in mice. However, DLX and a mouse Cyp2d inhibitor propranolol in both WT and Cyp1a2-KO mice lead to severe liver injury. The ALT levels increased for 2.9- and 8.7-fold in 50 mg/kg and 100 mg/kg groups, respectively in WT mice co-treated with propranolol. Similar increased folds of ALT were also observed in Cyp1a2-KO mice. H&E staining of mouse livers also confirmed the liver toxicity, presented as cell necrosis, in 100 mg/kg group in both WT and Cyp1a2-KO mice with the co-treatment of Cyp2d inhibitor. In summary, our findings suggests that impairing P450-mediated metabolism exacerbates DLX hepatoxicity <i>in vitro</i> and <i>in vivo</i>. Further studies are warranted to verify the roles of CYP1A2 and CYP2D6 in DLX liver toxicity using liver humanized mice and their inhibitors. This work was supported by the NIDDK (R01DK121970) and NICHD (R61/33HD099995) to Dr. Feng Li. Feng Li was also partially supported by the NICHD (P01 HD087157, R01HD110038) to Dr. Martin M. Matzuk." @default.
• W4377029582 created "2023-05-19" @default.
• W4377029582 creator A5000277180 @default.
• W4377029582 creator A5020229055 @default.
• W4377029582 creator A5046280891 @default.
• W4377029582 creator A5074564751 @default.
• W4377029582 creator A5079261300 @default.
• W4377029582 date "2023-05-18" @default.
• W4377029582 modified "2023-09-29" @default.
• W4377029582 title "Impairing Cytochrome P450-mediated metabolism aggravates the hepatoxicity of serotonin and norepinephrine reuptake inhibitor duloxetine" @default.
• W4377029582 doi "https://doi.org/10.1124/jpet.122.246460" @default.
• W4377029582 hasPublicationYear "2023" @default.
• W4377029582 type Work @default.
• W4377029582 citedByCount "0" @default.
• W4377029582 crossrefType "proceedings-article" @default.
• W4377029582 hasAuthorship W4377029582A5000277180 @default.
• W4377029582 hasAuthorship W4377029582A5020229055 @default.
• W4377029582 hasAuthorship W4377029582A5046280891 @default.
• W4377029582 hasAuthorship W4377029582A5074564751 @default.
• W4377029582 hasAuthorship W4377029582A5079261300 @default.
• W4377029582 hasBestOaLocation W43770295821 @default.
• W4377029582 hasConcept C126322002 @default.
• W4377029582 hasConcept C134018914 @default.
• W4377029582 hasConcept C170493617 @default.
• W4377029582 hasConcept C185592680 @default.
• W4377029582 hasConcept C2775864247 @default.
• W4377029582 hasConcept C2776134451 @default.
• W4377029582 hasConcept C2777828372 @default.
• W4377029582 hasConcept C2780092697 @default.
• W4377029582 hasConcept C31487548 @default.
• W4377029582 hasConcept C526171541 @default.
• W4377029582 hasConcept C55493867 @default.
• W4377029582 hasConcept C62231903 @default.
• W4377029582 hasConcept C71924100 @default.
• W4377029582 hasConcept C86745063 @default.
• W4377029582 hasConcept C98274493 @default.
• W4377029582 hasConceptScore W4377029582C126322002 @default.
• W4377029582 hasConceptScore W4377029582C134018914 @default.
• W4377029582 hasConceptScore W4377029582C170493617 @default.
• W4377029582 hasConceptScore W4377029582C185592680 @default.
• W4377029582 hasConceptScore W4377029582C2775864247 @default.
• W4377029582 hasConceptScore W4377029582C2776134451 @default.
• W4377029582 hasConceptScore W4377029582C2777828372 @default.
• W4377029582 hasConceptScore W4377029582C2780092697 @default.
• W4377029582 hasConceptScore W4377029582C31487548 @default.
• W4377029582 hasConceptScore W4377029582C526171541 @default.
• W4377029582 hasConceptScore W4377029582C55493867 @default.
• W4377029582 hasConceptScore W4377029582C62231903 @default.
• W4377029582 hasConceptScore W4377029582C71924100 @default.
• W4377029582 hasConceptScore W4377029582C86745063 @default.
• W4377029582 hasConceptScore W4377029582C98274493 @default.
• W4377029582 hasLocation W43770295821 @default.
• W4377029582 hasOpenAccess W4377029582 @default.
• W4377029582 hasPrimaryLocation W43770295821 @default.
• W4377029582 hasRelatedWork W1977911727 @default.
• W4377029582 hasRelatedWork W1992568187 @default.
• W4377029582 hasRelatedWork W2080412550 @default.
• W4377029582 hasRelatedWork W2083976782 @default.
• W4377029582 hasRelatedWork W2090977130 @default.
• W4377029582 hasRelatedWork W2410053991 @default.
• W4377029582 hasRelatedWork W2744352683 @default.
• W4377029582 hasRelatedWork W2790218409 @default.
• W4377029582 hasRelatedWork W3041630020 @default.
• W4377029582 hasRelatedWork W4283362117 @default.
• W4377029582 isParatext "false" @default.
• W4377029582 isRetracted "false" @default.
• W4377029582 workType "article" @default.